180 related articles for article (PubMed ID: 31591015)
1. Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor γ indole partial agonists.
Eeda V; Wu D; Lim HY; Wang W
Bioorg Med Chem Lett; 2019 Nov; 29(22):126664. PubMed ID: 31591015
[TBL] [Abstract][Full Text] [Related]
2. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
[TBL] [Abstract][Full Text] [Related]
3. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.
Wu D; Eeda V; Undi RB; Mann S; Stout M; Lim HY; Wang W
Mol Metab; 2021 Dec; 54():101363. PubMed ID: 34710641
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
Huang F; Zeng Z; Zhang W; Yan Z; Chen J; Yu L; Yang Q; Li Y; Yu H; Chen J; Wu C; Zhang XK; Su Y; Zhou H
Eur J Med Chem; 2021 Oct; 222():113542. PubMed ID: 34118723
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of alkoxyindolyl-3-acetic acid analogs as peroxisome proliferator-activated receptor-γ/δ agonists.
Gim HJ; Li H; Lee E; Ryu JH; Jeon R
Bioorg Med Chem Lett; 2013 Jan; 23(2):513-7. PubMed ID: 23265886
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
7. Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity.
Guasch L; Sala E; Valls C; Blay M; Mulero M; Arola L; Pujadas G; Garcia-Vallvé S
J Comput Aided Mol Des; 2011 Aug; 25(8):717-28. PubMed ID: 21691811
[TBL] [Abstract][Full Text] [Related]
8. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
[TBL] [Abstract][Full Text] [Related]
9. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
10. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
Porskjær Christensen L; Bahij El-Houri R
Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
[TBL] [Abstract][Full Text] [Related]
11. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
[TBL] [Abstract][Full Text] [Related]
12. Design, development and evaluation of novel dual PPARδ/PPARγ agonists.
Gathiaka S; Nanayakkara G; Boncher T; Acevedo O; Wyble J; Patel S; Patel A; Shane ME; Bonkowski B; Wieczorek J; Rong Y; Huggins K; Smith F; Amin RH
Bioorg Med Chem Lett; 2013 Feb; 23(3):873-9. PubMed ID: 23273519
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of [[(heterocycloamino)alkoxy] benzyl]-2,4-thiazolidinediones as PPARgamma agonists.
Jeon R; Kim YJ; Cheon Y; Ryu JH
Arch Pharm Res; 2006 May; 29(5):394-9. PubMed ID: 16756084
[TBL] [Abstract][Full Text] [Related]
15. (S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonist.
Morishita K; Miike T; Takeda S; Fukui M; Ito Y; Kitao T; Ozawa SI; Hirono S; Shirahase H
Chem Pharm Bull (Tokyo); 2019; 67(11):1211-1224. PubMed ID: 31685749
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
18. Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists.
Furukawa A; Arita T; Fukuzaki T; Satoh S; Mori M; Honda T; Matsui Y; Wakabayashi K; Hayashi S; Araki K; Ohsumi J
Bioorg Med Chem Lett; 2012 Feb; 22(3):1348-51. PubMed ID: 22225641
[TBL] [Abstract][Full Text] [Related]
19. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
[TBL] [Abstract][Full Text] [Related]
20. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
Jang JY; Bae H; Lee YJ; Choi YI; Kim HJ; Park SB; Suh SW; Kim SW; Han BW
Sci Rep; 2018 Jan; 8(1):31. PubMed ID: 29311579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
